Sanofi and Regeneron's multi-blockbuster approved for sixth indication
Sanofi and Regeneron’s best-selling antibody drug Dupixent (dupilumab) now has another indication under its belt.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Sanofi ready with phase II data for new eczema drug
For subscribers
FDA approves Leo Pharma's eczema drug for adolescents
For subscribers
Dupixent becomes ninefold blockbuster
For subscribers